NEW YORK – Agilent Technologies said Friday that it plans to offer a combined $1.2 billion in senior notes.

纽约——安捷伦科技（Agilent Technologies）周五表示，计划提供总计12亿美元的高级票据。

In a prospectus filed with the US Securities and Exchange Commission, the company said that proceeds from the offering will be used to partially finance the acquisition of Canadian contract development manufacturing organization Biovectra and to prepay some of its outstanding loan under its term loan facility.

在向美国证券交易委员会提交的招股说明书中，该公司表示，此次发行的收益将用于部分资助收购加拿大合同开发制造组织Biovectra，并预付其定期贷款机制下的部分未偿还贷款。

Proceeds will also be used for general corporate purposes. .

收益也将用于一般公司用途。

The offering is for $600 million of 4.2 percent interest senior notes due Sept. 9, 2027, and $600 million of 4.75 percent interest senior notes due Sept. 9, 2034. Under the terms of the deal, Agilent will issue and sell the unsecured notes to a group of underwriters led by BofA Securities, JP Morgan Securities, Mizuho Securities USA, and Wells Fargo Securities.

此次发行的是2027年9月9日到期的6亿美元4.2%利息的高级票据和2034年9月9日到期的6亿美元4.75%利息的高级票据。根据交易条款，安捷伦将向美国银行证券、摩根大通证券、美国瑞穗证券和富国银行证券牵头的一组承销商发行和出售无担保票据。

The offering is expected to close on Sept. 9..

此次发行预计将于9月9日结束。。

The 2027 notes will be issued at a price of 99.866 percent of their principal amount and the 2034 notes will be issued at a price of 99.638 percent of their principal amount.

2027年票据的发行价格为其本金的99.866%，2034年票据的发行价格为其本金的99.638%。

Agilent said in July that it was acquiring Biovectra in a $925 million deal that would expand the company's capabilities for biopharma customers. Biovectra is a producer of biologics and complex chemistry products for pharma customers, and Agilent said that the deal was expected to close before 2025..

。Biovectra是一家为制药客户生产生物制剂和复杂化学产品的公司，安捷伦表示，该交易预计将在2025年之前完成。。

The 2027 notes will be subject to a special mandatory redemption event If the Biovectra acquisition isn't completed by the later of July 21, 2025, or five days after any extensions of the end date in the purchase agreement. The 2034 notes, however, are not subject to mandatory redemption provisions..

如果Biovectra收购未能在2025年7月21日或购买协议中终止日期延期后五天内完成，2027年票据将受到特殊的强制赎回事件的约束。然而，2034年票据不受强制赎回规定的约束。。